CAS:PRO's EV-to-EBITDA is ranked better than 81.87% of 739
companies
in the Drug Manufacturers industry
Industry Median: 12.78
vs CAS:PRO: 6.20
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's PE Ratio (TTM) for today is calculated as:
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's share price for today is MAD1269.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was MAD0.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM EV-to-EBITDA Chart
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Annual Data
CAS:PRO vs ZTS, UTHR, VTRS: EV-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM EV-to-EBITDA vs Drug Manufacturers Industry
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's current Enterprise Value is MAD711.8 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was MAD114.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) has a EV-to-EBITDA of 6.20 as of Jul. 09, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM. This is 29% below median its historical median of 8.79. Over the past decade, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's EV-to-EBITDA has ranged from 4.84 to 13.42. According to the industry distribution chart, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM ranks #134 out of 739 companies in the Drug Manufacturers industry, placing it in the top 18.1%.
Is PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's EV-to-EBITDA too high?
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's current EV-to-EBITDA of 6.20 is 29% below median its 10-year median of 8.79. Over the past 10 years, this metric has ranged from a low of 4.84 to a high of 13.42. The Drug Manufacturers industry median EV-to-EBITDA is 12.78. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's value of 6.20 is 51.5% below this industry median. Based on the distribution chart, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM ranks #134 out of 739 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM has a GF Score™ of 87/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM ranks #134 out of 739 companies for EV-to-EBITDA. This places PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM in the top 18% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 12.78. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's value of 6.20 is 51.5% below this benchmark. Historically, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's own EV-to-EBITDA has ranged from 4.84 to 13.42 over the past decade. While the company's 10-year median is 8.79 vs. the industry median of 12.78, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.78, based on 739 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's current EV-to-EBITDA of 6.20 is 51.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's current EV-to-EBITDA is 6.20, which is 29% below median its own 10-year median of 8.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM stock overvalued right now?
Based on GuruFocus' analysis, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) is currently considered Fairly Valued. The stock's GF Value™ is MAD1,333.32, compared to a current price of MAD1,269.00 — trading 4.8% below its estimated fair value. The current EV-to-EBITDA is 6.20, which is 29% below median its 10-year median of 8.79 and 51.5% below the Drug Manufacturers industry median of 12.78. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's overall GF Score™ is 87/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO), the current EV-to-EBITDA is 6.20 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) Overvalued in 2026?
Based on GuruFocus' analysis, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM stock appears to be undervalued.
The current stock price of MAD1,269.00 is trading 4.8% below its estimated GF Value™ of MAD1,333.32.
GuruFocus considers PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM to be Fairly Valued.
Key valuation signals for CAS:PRO:
EV-to-EBITDA: 6.20 (29% below median its 10-year median of 8.79)
GF Value™: MAD1,333.32 vs. price of MAD1,269.00 (4.8% below fair value)
Industry Position: 51.5% below the Drug Manufacturers median (#134 of 739)
No single metric tells the full story. See the CAS:PRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Business Description
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM is engaged in production, marketing, import and export of pharmaceuticals, parapharmaceuticals, dermopharmaceuticals and cosmetics.
87GF Score
Get the complete analysis for CAS:PRO
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAS:PRO has been successfully added to your 
